Beam Therapeutics director granted 19,676 stock options

Beam Therapeutics Inc. director Guindo Chirfi received a stock option grant as equity compensation.

Rhea-AI Filing Summary

Beam Therapeutics Inc. director Guindo Chirfi received a stock option grant as equity compensation. The award covers 19,676 shares of Beam common stock at an exercise price of $29.55 per share, expiring on June 3, 2036. The option vests in full on the earlier of the first anniversary of the grant date or immediately before next year’s annual meeting of stockholders, as long as Chirfi continues serving on the board through the vesting date. This is a non-cash, routine director compensation grant and not an open-market share purchase or sale.

Insider Trade Summary

Grant/Award: 19,676 shares

Grant/Award 1 txn

Insider Guindo Chirfi

Role Director

Type	Security	Shares	Price	Value
Grant/Award	Stock Option (Right to Buy)	19,676	$0.00	$0.00

Holdings After Transaction: Stock Option (Right to Buy) — 19,676 contracts (Direct)

Footnotes (1)

1. F1. The option vests in full on the earlier of the first anniversary of the date of grant and immediately prior to the date of the next year's annual meeting of stockholders, subject to the reporting person's continued service to the board of directors of Beam Therapeutics Inc. through the vesting date.

Key Figures

Option grant size: 19,676 shares Exercise price: $29.55 per share Shares after transaction: 19,676 derivative units +3 more

6 metrics

Option grant size 19,676 shares Underlying Beam Therapeutics common stock

Exercise price $29.55 per share Stock option strike price

Shares after transaction 19,676 derivative units Total options held after grant

Expiration date June 3, 2036 Option expiration

Transaction code A Grant, award, or other acquisition

Transaction direction acquire Equity award to director

Key Terms

Stock Option (Right to Buy), exercise price, expiration date, underlying security, +2 more

6 terms

Stock Option (Right to Buy) financial

"security_title: Stock Option (Right to Buy)"

exercise price financial

"conversion_or_exercise_price: 29.5500"

The exercise price is the fixed amount at which you can buy or sell an asset, like a stock, when using an options contract. It matters because it helps determine whether exercising the option will be profitable or not, depending on the current market price. Think of it as the set price you agree on today to buy or sell later.

expiration date financial

"expiration_date: 2036-06-03T00:00:00.000Z"

The expiration date is the deadline after which a financial contract, such as an option or a futures agreement, is no longer valid or can be exercised. It matters to investors because it determines the timeframe during which they can take action or benefit from the contract, similar to how a coupon or a food item has a limited period of usefulness. Once the expiration date passes, the contract loses its value or ability to be used.

underlying security financial

"underlying_security_title: Common Stock"

vesting financial

"The option vests in full on the earlier of the first anniversary"

Vesting is the process by which you earn full ownership of something, like company stock or a retirement benefit, over time. It’s like earning the right to keep a gift piece by piece the longer you stay with a company, making sure employees stay committed before they receive all the benefits.

annual meeting of stockholders financial

"immediately prior to the date of the next year's annual meeting of stockholders"

FAQ

AI-generated questions and answers. How Rhea-AI works. Not financial advice.

What did Beam Therapeutics (BEAM) director Guindo Chirfi report in this Form 4?

Guindo Chirfi reported receiving a stock option grant from Beam Therapeutics. The award covers 19,676 shares of common stock, giving the director the right to buy shares at a fixed exercise price in the future, subject to vesting conditions.

How many Beam Therapeutics (BEAM) shares are covered by Chirfi’s new stock option?

The option grant covers 19,676 underlying shares of Beam Therapeutics common stock. These shares are not issued immediately; Chirfi can acquire them later by exercising the option at the stated strike price once the award has fully vested.

What is the exercise price of Guindo Chirfi’s Beam Therapeutics (BEAM) stock option?

The option has an exercise price of $29.55 per share. This means Chirfi can buy Beam Therapeutics common stock at $29.55 once the option vests and is exercised, regardless of the market price at that future time.

When does Guindo Chirfi’s Beam Therapeutics (BEAM) option vest?

The option vests in full on the earlier of the first anniversary of the grant date or immediately before next year’s annual meeting. Vesting requires Chirfi’s continued service on Beam Therapeutics’ board of directors through that vesting date.

When does the reported Beam Therapeutics (BEAM) stock option held by Chirfi expire?

The stock option expires on June 3, 2036. After that expiration date, Chirfi would no longer be able to exercise the option to purchase Beam Therapeutics common shares at the fixed $29.55 exercise price granted in this award.

Is Guindo Chirfi buying or selling Beam Therapeutics (BEAM) shares in this Form 4?

This Form 4 reflects an option grant, not an open-market trade. Chirfi is acquiring the right to buy shares in the future, but no common shares were bought or sold in the market as part of this reported transaction.

AI-generated analysis. How Rhea-AI works. Not financial advice.

Form 4 Insider Transactions: What Each Field Means →

See more from StockTitan in Google Search and AI answers. Adds StockTitan as a preferred source · opens Google

Add on Google Not now

Accepted by SEC EDGAR 06/05/2026 - 04:05 PM EDT Learn about SEC filing dates

SEC Form 4

FORM 4

UNITED STATES SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549

STATEMENT OF CHANGES IN BENEFICIAL OWNERSHIP

Filed pursuant to Section 16(a) of the Securities Exchange Act of 1934
or Section 30(h) of the Investment Company Act of 1940

OMB APPROVAL

OMB Number:			3235-0287
Estimated average burden
hours per response:			0.5

Check this box if no longer subject to Section 16. Form 4 or Form 5 obligations may continue. See Instruction 1(b).

Check this box to indicate that a transaction was made pursuant to a contract, instruction or written plan for the purchase or sale of equity securities of the issuer that is intended to satisfy the affirmative defense conditions of Rule 10b5-1(c). See Instruction 10.

1. Name and Address of Reporting Person^*

Guindo Chirfi

(Last) (First) (Middle)

C/O BEAM THERAPEUTICS INC.,

238 MAIN STREET

(Street)

CAMBRIDGE MASSACHUSETTS 02142

(City) (State) (Zip)

UNITED STATES

(Country)

2. Issuer Name and Ticker or Trading Symbol
Beam Therapeutics Inc. [ BEAM ]

5. Relationship of Reporting Person(s) to Issuer
(Check all applicable)

X	Director		10% Owner
	Officer (give title below)		Other (specify below)

2a. Foreign Trading Symbol

3. Date of Earliest Transaction (Month/Day/Year)
06/03/2026

6. Individual or Joint/Group Filing (Check Applicable Line)

X	Form filed by One Reporting Person
	Form filed by More than One Reporting Person

4. If Amendment, Date of Original Filed (Month/Day/Year)

Table I - Non-Derivative Securities Acquired, Disposed of, or Beneficially Owned
1. Title of Security (Instr. 3)	2. Transaction Date (Month/Day/Year)	2A. Deemed Execution Date, if any (Month/Day/Year)	3. Transaction Code (Instr. 8)		4. Securities Acquired (A) or Disposed Of (D) (Instr. 3, 4 and 5)			5. Amount of Securities Beneficially Owned Following Reported Transaction(s) (Instr. 3 and 4)	6. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	7. Nature of Indirect Beneficial Ownership (Instr. 4)
			Code	V	Amount	(A) or (D)	Price

Table II - Derivative Securities Acquired, Disposed of, or Beneficially Owned (e.g., puts, calls, warrants, options, convertible securities)
1. Title of Derivative Security (Instr. 3)	2. Conversion or Exercise Price of Derivative Security	3. Transaction Date (Month/Day/Year)	3A. Deemed Execution Date, if any (Month/Day/Year)	4. Transaction Code (Instr. 8)		5. Number of Derivative Securities Acquired (A) or Disposed of (D) (Instr. 3, 4 and 5)		6. Date Exercisable and Expiration Date (Month/Day/Year)		7. Title and Amount of Securities Underlying Derivative Security (Instr. 3 and 4)		8. Price of Derivative Security (Instr. 5)	9. Number of derivative Securities Beneficially Owned Following Reported Transaction(s) (Instr. 4)	10. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	11. Nature of Indirect Beneficial Ownership (Instr. 4)
				Code	V	(A)	(D)	Date Exercisable	Expiration Date	Title	Amount or Number of Shares
Stock Option (Right to Buy)	$29.55	06/03/2026		A		19,676		(1)	06/03/2036	Common Stock	19,676	$0	19,676	D

Explanation of Responses:

1. The option vests in full on the earlier of the first anniversary of the date of grant and immediately prior to the date of the next year's annual meeting of stockholders, subject to the reporting person's continued service to the board of directors of Beam Therapeutics Inc. through the vesting date.

	By: /s/ Christine Bellon, Attorney-in-fact	06/05/2026
	** Signature of Reporting Person	Date
Reminder: Report on a separate line for each class of securities beneficially owned directly or indirectly.
* If the form is filed by more than one reporting person, see Instruction 4 (b)(v).
** Intentional misstatements or omissions of facts constitute Federal Criminal Violations See 18 U.S.C. 1001 and 15 U.S.C. 78ff(a).
Note: File three copies of this Form, one of which must be manually signed. If space is insufficient, see Instruction 6 for procedure.
Persons who respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB Number.
* Form 4: SEC 1474 (03-26)